Schizencephaly: Etiopathogenesis, Classification, Therapeutic, and Rehabilitative Approach

Abstract

Schizencephaly is an uncommon anomaly in neuronal migration characterized by complete clefts that extend from the pia mater to the ependymal surface of the ventricular system. These clefts are encompassed by displaced gray matter and filled with cerebrospinal fluid. Typically, they are found most often in the frontal lobe or the area around the lateral sulcus and can occur on one or both sides. The size, location, and type of these clefts carry significant clinical and prognostic implications. Moreover, they are frequently associated with other central nervous system malformations, including the absence of the septum pellucidum, septo-optic dysplasia, optic nerve hypoplasia, pachygyria, polymicrogyria, cortical dysplasia, heterotopia, and dysplasia of the corpus callosum. Occurrence of schizencephaly is almost always sporadic but its etiopathogenesis is yet to be fully understood. Most likely environmental factors, including exposure to teratogens, viral infections, and maternal factors, operate jointly with genetic defects. To date COL4A1, EMX2, SHH, and SIX3 are the genes identified as possible pathogenetic target. It is interesting to notice that schizencephaly is commonly seen in abandoned or adopted children, as proof of causative effect of intrautero insults. Clinical presentations widely vary and symptoms include a spectrum of cognitive impairment, limb paresis/tetraparesis, and epileptic seizures either with early or late onset; anyway, none of these symptoms is ever-present and patients with schizencephaly can also have normal neurocognitive and motor development. Diagnostic gold standard for schizencephaly is magnetic resonance imaging, which allows to identify and characterize typical clefts. Treatment of schizencephaly is symptomatic and supportive and depends on the severity of morbidity resulting from the malformation. Therapy includes antiepileptic drugs, psychomotor rehabilitation, and in selected cases surgical approach.

Keywords

developmental neurobiology - migration - environmental factors - genetics

^* These authors contributed equally to this article.

Publikationsverlauf

Eingereicht: 05. Dezember 2023

Angenommen: 04. April 2024

Artikel online veröffentlicht:
11. Mai 2024

• References

• 1 Hung PC, Wang HS, Chou ML. et al. Schizencephaly in children: a single medical center retrospective study. Pediatr Neonatol 2018; 59 (06) 573-580
• 2 Pavone P, Spalice A, Polizzi A, Parisi P, Ruggieri M. Ohtahara syndrome with emphasis on recent genetic discovery. Brain Dev 2012; 34 (06) 459-468
• 3 Barkovich AJ, Kjos BO. Schizencephaly: correlation of clinical findings with MR characteristics. AJNR Am J Neuroradiol 1992; 13 (01) 85-94
• 4 Ruggieri M, Rizzo R, Pavone P, Baieli S, Sorge G, Happle R. Temporal triangular alopecia in association with mental retardation and epilepsy in a mother and daughter. Arch Dermatol 2000; 136 (03) 426-427
• 5 Bansal N, Maini B, Bhardwaj AK, Sharma R. Schizencephaly of open and closed lip type in the same patient: an extremely rare occurrence. J Pediatr Neurosci 2012; 7 (02) 109-110
• 6 Ruggieri M, Iannetti P, Clementi M. et al. Neurofibromatosis type 1 and infantile spasms. Childs Nerv Syst 2009; 25 (02) 211-216
• 7 Griffiths PD. Schizencephaly revisited. Neuroradiology 2018; 60 (09) 945-960
• 8 Pavone P, Praticò AD, Pavone V. et al. Ataxia in children: early recognition and clinical evaluation. Ital J Pediatr 2017; 43 (01) 6
• 9 Halabuda A, Klasa L, Kwiatkowski S, Wyrobek L, Milczarek O, Gergont A. Schizencephaly-diagnostics and clinical dilemmas. Childs Nerv Syst 2015; 31 (04) 551-556
• 10 Ruggieri M. Mosaic (segmental) neurofibromatosis type 1 (NF1) and type 2 (NF2): no longer neurofibromatosis type 5 (NF5). Am J Med Genet 2001; 101 (02) 178-180
• 11 Nabavizadeh SA, Zarnow D, Bilaniuk LT, Schwartz ES, Zimmerman RA, Vossough A. Correlation of prenatal and postnatal MRI findings in schizencephaly. AJNR Am J Neuroradiol 2014; 35 (07) 1418-1424
• 12 Ruggieri M, McShane MA. Parental view of epilepsy in Angelman syndrome: a questionnaire study. Arch Dis Child 1998; 79 (05) 423-426
• 13 Denis D, Chateil JF, Brun M. et al. Schizencephaly: clinical and imaging features in 30 infantile cases. Brain Dev 2000; 22 (08) 475-483
• 14 Ruggieri M, Huson SM. The neurofibromatoses. An overview. Ital J Neurol Sci 1999; 20 (02) 89-108
• 15 Lyu J, Hu J, Wang X. et al. Association of fluid-attenuated inversion recovery vascular hyperintensity with ischaemic events in internal carotid artery or middle cerebral artery occlusion. Stroke Vasc Neurol 2023; 8 (01) 69-76
• 16 Ruggieri M. Cutis tricolor: congenital hyper- and hypopigmented lesions in a background of normal skin with and without associated systemic features: further expansion of the phenotype. Eur J Pediatr 2000; 159 (10) 745-749
• 17 Hung PC, Wang HS, Yeh YS, Lui TN, Lee ST. Coexistence of schizencephaly and intracranial arteriovenous malformation in an infant. AJNR Am J Neuroradiol 1996; 17 (10) 1921-1922
• 18 Ruggieri M, Praticò AD, Serra A. et al. Early history of neurofibromatosis type 2 and related forms: earliest descriptions of acoustic neuromas, medical curiosities, misconceptions, landmarks and the pioneers behind the eponyms. Childs Nerv Syst 2017; 33 (04) 549-560
• 19 Dies KA, Bodell A, Hisama FM. et al. Schizencephaly: association with young maternal age, alcohol use, and lack of prenatal care. J Child Neurol 2013; 28 (02) 198-203
• 20 Pavone P, Rizzo R, Conti I. et al. Primary headaches in children: clinical findings on the association with other conditions. Int J Immunopathol Pharmacol 2012; 25 (04) 1083-1091
• 21 Merello E, Swanson E, De Marco P. et al. No major role for the EMX2 gene in schizencephaly. Am J Med Genet A 2008; 146A [phone]
• 22 Falsaperla R, D'Angelo G, Praticò AD. et al. Ketogenic Diet for Infants with Epilepsy: A Literature Review. Epilepsy & Beavior; 2020: 112
• 23 Harada T, Uegaki T, Arata K, Tsunetou T, Taniguchi F, Harada T. Schizencephaly and porencephaly due to fetal intracranial hemorrhage: a report of two cases. Yonago Acta Med 2018; 60 (04) 241-245
• 24 Pavone P, Praticò AD, Falsaperla R. et al. Congenital generalized hypertrichosis: the skin as a clue to complex malformation syndromes. Ital J Pediatr 2015; 41: 55
• 25 Brunelli S, Faiella A, Capra V. et al. Germline mutations in the homeobox gene EMX2 in patients with severe schizencephaly. Nat Genet 1996; 12 (01) 94-96
• 26 Pavone P, Praticò AD, Ruggieri M, Falsaperla R. Hypomelanosis of Ito: a round on the frequency and type of epileptic complications. Neurol Sci 2015; 36 (07) 1173-1180
• 27 Hehr U, Pineda-Alvarez DE, Uyanik G. et al. Heterozygous mutations in SIX3 and SHH are associated with schizencephaly and further expand the clinical spectrum of holoprosencephaly. Hum Genet 2010; 127 (05) 555-561
• 28 Pavone P, Praticò AD, Ruggieri M. et al. Acquired peripheral neuropathy: a report on 20 children. Int J Immunopathol Pharmacol 2012; 25 (02) 513-517
• 29 Geng X, Speirs C, Lagutin O. et al. Haploinsufficiency of Six3 fails to activate Sonic hedgehog expression in the ventral forebrain and causes holoprosencephaly. Dev Cell 2008; 15 (02) 236-247
• 30 Pratico AD, Ruggieri M, Falsaperla R, Pavone P. A probable topiramate-induced limbs paraesthesia and rigid fingers flexion. Curr Drug Saf 2018; 13 (02) 131-136
• 31 Del Bene F, Tessmar-Raible K, Wittbrodt J. Direct interaction of geminin and Six3 in eye development. Nature 2004; 427 (6976) 745-749
• 32 Pavone P, Nigro F, Falsaperla R. et al. Hemihydranencephaly: living with half brain dysfunction. Ital J Pediatr 2013; 39: 3
• 33 Kuban KC, Teele RL, Wallman J. Septo-optic-dysplasia-schizencephaly. Radiographic and clinical features. Pediatr Radiol 1989; 19 (03) 145-150
• 34 Pavone P, Praticò AD, Gentile G. et al. A neurocutaneous phenotype with paired hypo- and hyperpigmented macules, microcephaly and stunted growth as prominent features. Eur J Med Genet 2016; 59 (05) 283-289
• 35 Rege SV, Patil H. Bilateral giant open-lip schizencephaly: a rare case report. J Pediatr Neurosci 2016; 11 (02) 128-130
• 36 Ruggieri M, Praticò AD, Caltabiano R, Polizzi A. Rediagnosing one of Smith's patients (John McCann) with “neuromas tumours” (1849). Neurol Sci 2017; 38 (03) 493-499
• 37 Aniskiewicz AS, Frumkin NL, Brady DE, Moore JB, Pera A. Magnetic resonance imaging and neurobehavioral correlates in schizencephaly. Arch Neurol 1990; 47 (08) 911-916
• 38 Ruggieri M, Polizzi A, Marceca GP, Catanzaro S, Praticò AD, Di Rocco C. Introduction to phacomatoses (neurocutaneous disorders) in childhood. Childs Nerv Syst 2020; 36 (10) 2229-2268
• 39 Braga VL, da Costa MDS, Riera R. et al. Schizencephaly: a review of 734 patients. Pediatr Neurol 2018; 87: 23-29
• 40 Incorpora G, Pavone P, Castellano-Chiodo D, Praticò AD, Ruggieri M, Pavone L. Gelastic seizures due to hypothalamic hamartoma: rapid resolution after endoscopic tumor disconnection. Neurocase 2013; 19 (05) 458-461
• 41 Granata T, Freri E, Caccia C, Setola V, Taroni F, Battaglia G. Schizencephaly: clinical spectrum, epilepsy, and pathogenesis. J Child Neurol 2005; 20 (04) 313-318
• 42 Leonardi S, Praticò AD, Lionetti E, Spina M, Vitaliti G, La Rosa M. Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children. World J Gastroenterol 2012; 18 (40) 5729-5733
• 43 Hakimi T, Mohammad Qasem K. Bilateral open lip schizencephaly. Ann Med Surg (Lond) 2021; 73: 103204
• 44 Palano GM, Praticò AD, Praticò ER. et al. Intossicazione accidentale da alcol etilico in un lattante di 30 giorni. Quadro clinico e follow-up neurologico. Minerva Pediatr 2007; 59 (03) 275-279
• 45 Patwal R, Pai NM, Ganjekar S. et al. Schizencephaly and the neurodevelopmental model of psychosis. Neurol India 2022; 70 (02) 740-743
• 46 Fiumara A, Lanzafame G, Arena A. et al. COVID-19 pandemic outbreak and its psychological impact on patients with rare lysosomal diseases. J Clin Med 2020; 9 (09) 2716
• 47 Lopes CF, Cendes F, Piovesana AM. et al. Epileptic features of patients with unilateral and bilateral schizencephaly. J Child Neurol 2006; 21 (09) 757-760
• 48 Praticò AD, Leonardi S. Immunotherapy for food allergies: a myth or a reality?. Immunotherapy 2015; 7 (02) 147-161
• 49 Granata T, Battaglia G, D'Incerti L. et al. Schizencephaly: neuroradiologic and epileptologic findings. Epilepsia 1996; 37 (12) 1185-1193
• 50 Salafia S, Praticò AD, Pizzo E, Greco F, Di Bella D. Hemiconvulsion-hemiplegia-epilepsy syndrome. Magnetic resonance findings in a 3-year-old boy. Neurol Neurochir Pol 2013; 47 (06) 584-589
• 51 Bhatnagar S, Kuber R, Shah D, Kulkarni V. Unilateral closed lip schizencephaly with septo-optic dysplasia. Ann Med Health Sci Res 2014; 4 (02) 283-285
• 52 Praticò AD, Ruggieri M. COVID-19 vaccination for children: may be necessary for the full eradication of the disease. Pediatr Res 2021; 90 (06) 1102-1103
• 53 Veerapaneni P, Veerapaneni KD, Yadala S. Schizencephaly. July 31, 2023. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023
• 54 Ruggieri M, Polizzi A, Catanzaro S, Bianco ML, Praticò AD, Di Rocco C. Neurocutaneous melanocytosis (melanosis). Childs Nerv Syst 2020; 36 (10) 2571-2596
• 55 Rios LT, Araujo Júnior E, Nardozza LM, Caetano AC, Moron AF, Martins MdaG. Prenatal and postnatal schizencephaly findings by 2D and 3D ultrasound: pictorial essay. J Clin Imaging Sci 2012; 2: 30
• 56 Praticò AD, Mistrello G, La Rosa M. et al. Immunotherapy: a new horizon for egg allergy?. Expert Rev Clin Immunol 2014; 10 (05) 677-686
• 57 Kopyta I, Jamroz E, Marszal E, Kluczewska E. Schizencephaly–clinical and radiological presentation of pediatric patients [in Polish]. Wiad Lek 2006; 59 (7-8): 471-476
• 58 Praticò AD. COVID-19 pandemic for pediatric health care: disadvantages and opportunities. Pediatr Res 2021; 89 (04) 709-710
• 59 Zhang J, Yang Z, Yang Z, He X, Hou Y, Wang Y. Successful surgery for refractory seizures associated with bilateral schizencephaly: two case reports and literature review. Neurol Sci 2016; 37 (07) 1079-1088
• 60 Praticò AD, Giallongo A, Arrabito M. et al. SCN2A and its related epileptic phenotypes. J Pediatr Neurol 2023; 21 (03) 173-185
• 61 Kułak W, Okurowska-Zawada B, Gościk E, Sienkiewicz D, Paszko-Patej G, Kubas B. Schizencephaly as a cause of spastic cerebral palsy. Adv Med Sci 2011; 56 (01) 64-70
• 62 Praticò AD, Falsaperla R, Comella M, Belfiore G, Polizzi A, Ruggieri M. Case report: a gain-of-function of hamartin may lead to a distinct “inverse TSC1-hamartin” phenotype characterized by reduced cell growth. Front Pediatr 2023; 11: 1101026
• 63 Polizzi A, Finocchiaro M, Parano E, Pavone P, Musumeci S, Polizzi A. Recurrent peripheral neuropathy in a girl with celiac disease. J Neurol Neurosurg Psychiatry 2000; 68 (01) 104-105
• 64 Polizzi A, Pavone P, Parano E, Incorpora G, Ruggieri M. Lack of progression of brain atrophy in Aicardi-Goutières syndrome. Pediatr Neurol 2001; 24 (04) 300-302
• 65 Nicita F, Ruggieri M, Polizzi A. et al. Seizures and epilepsy in Sotos syndrome: analysis of 19 Caucasian patients with long-term follow-up. Epilepsia 2012; 53 (06) e102-e105
• 66 Leuzzi V, Mastrangelo M, Polizzi A. et al. Report of two never treated adult sisters with aromatic L-amino Acid decarboxylase deficiency: a portrait of the natural history of the disease or an expanding phenotype?. JIMD Rep 2015; 15: 39-45
• 67 Ruggieri M, Polizzi A. From Aldrovandi's “Homuncio” (1592) to Buffon's girl (1749) and the “Wart Man” of Tilesius (1793): antique illustrations of mosaicism in neurofibromatosis?. J Med Genet 2003; 40 (03) 227-232
• 68 Marciniak C, McAllister P, Walker H. et al; International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group. Efficacy and safety of abobotulinumtoxinA (dysport) for the treatment of hemiparesis in adults with upper limb spasticity previously treated with botulinum toxin: subanalysis from a phase 3 randomized controlled trial. PM R 2017; 9 (12) 1181-1190
• 69 Santamato A, Ranieri M, Solfrizzi V. et al. High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?. Expert Opin Drug Metab Toxicol 2016; 12 (08) 843-846
• 70 Gracies JM, Jech R, Valkovic P. et al. When can maximal efficacy occur with repeat botulinum toxin injection in upper limb spastic paresis?. Brain Commun 2020; 3 (01) fcaa201
• 71 Vecchio M, Gracies JM, Panza F. et al. Change in coefficient of fatigability following rapid, repetitive movement training in post-stroke spastic paresis: a prospective open-label observational study. J Stroke Cerebrovasc Dis 2017; 26 (11) 2536-2540
• 72 Chiaramonte R, Pavone P, Vecchio M. Speech rehabilitation in dysarthria after stroke: a systematic review of the studies. Eur J Phys Rehabil Med 2020; 56 (05) 547-562
• 73 Chiaramonte R, Vecchio M. Dysarthria and stroke. The effectiveness of speech rehabilitation. A systematic review and meta-analysis of the studies. Eur J Phys Rehabil Med 2021; 57 (01) 24-43
• 74 Floresta G, Patamia V, Gentile D. et al. Repurposing of FDA-approved drugs for treating iatrogenic botulism: a paired 3D-QSAR/Docking Approach^† . ChemMedChem 2020; 15 (02) 256-262
• 75 Gentile D, Floresta G, Patamia V. et al. An integrated Pharmacophore/Docking/3D-QSAR approach to screening a large library of products in search of future botulinum neurotoxin a inhibitors. Int J Mol Sci 2020; 21 (24) 9470